Loading...
XNASARGX
Market cap37bUSD
Dec 20, Last price  
623.82USD
1D
-0.35%
1Q
17.04%
IPO
2,755.01%
Name

argenx SE

Chart & Performance

D1W1MN
XNAS:ARGX chart
P/E
P/S
30.71
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
9.71%
Rev. gr., 5y
118.59%
Revenues
1.23b
+198.56%
1,458,1032,183,4583,696,5944,567,3427,493,49415,473,68643,687,16524,573,32478,168,96644,800,993497,277,000410,746,0001,226,316,000
Net income
-295m
L-58.42%
0000000000-408,265,000-709,594,000-295,053,000
CFO
-420m
L-51.28%
0000011,146,98500150,757,2360-606,812,000-862,807,000-420,327,000
Earnings
Feb 26, 2025

Profile

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
IPO date
Jul 10, 2014
Employees
843
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,226,316
198.56%
410,746
-17.40%
497,277
1,009.97%
Cost of revenue
1,582,488
1,164,929
1,458,177
Unusual Expense (Income)
NOPBT
(356,172)
(754,183)
(960,900)
NOPBT Margin
Operating Taxes
(9,443)
(19,720)
8,522
Tax Rate
NOPAT
(346,729)
(734,463)
(969,422)
Net income
(295,053)
-58.42%
(709,594)
73.81%
(408,265)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
1,196,731
755,485
1,091,326
BB yield
-5.50%
-3.67%
-6.10%
Debt
Debt current
4,646
3,417
3,509
Long-term debt
35,354
21,435
19,421
Deferred revenue
Other long-term liabilities
1,449
869
417
Net debt
(3,186,999)
(2,208,177)
(2,366,967)
Cash flow
Cash from operating activities
(420,327)
(862,807)
(606,812)
CAPEX
(812)
(103,823)
(121,434)
Cash from investing activities
308,210
(461,184)
(347,070)
Cash from financing activities
1,336,727
843,757
1,121,342
FCF
(676,282)
(941,622)
(973,588)
Balance
Cash
3,179,844
2,192,548
2,336,728
Long term investments
47,155
40,481
53,169
Excess cash
3,165,683
2,212,492
2,365,033
Stockholders' equity
3,325,782
(1,496,180)
(928,551)
Invested Capital
953,273
4,319,994
3,470,342
ROIC
ROCE
EV
Common stock shares outstanding
57,169
54,381
51,076
Price
380.43
0.42%
378.83
8.18%
350.19
19.08%
Market cap
21,748,899
5.57%
20,601,295
15.18%
17,886,244
33.93%
EV
24,213,397
18,393,118
15,519,277
EBITDA
(244,865)
(649,841)
(955,033)
EV/EBITDA
Interest
904
3,906
1,096
Interest/NOPBT